Ultrasonic Bioelectronics vs. Airborne Sensing: StimDust and the Legacy of Smart Dust [DARPA BAA 97-43]

A source is testimony, not proof. Citing one is a provenance fact — it records who said what, where — and never a verification that the claim is true.

Who is named

The characters and things this document talks about — 8 in alls. Each links to everything else the record knows about them.

Claims made

Every claim in this document. Firsthand = asserted on its own basis; secondhand = recounted from elsewhere, carrying no independent weight.

• StimDust was developed by UC Berkeley engineers as a sub-millimeter implant that converts external ultrasound waves into electrical stims for targeted peripheral nerve modulation.

  UC Berkeley engineers developed StimDust as a sub-millimeter implant that converts external ultrasound waves into electrical stims for targeted peripheral nerve modulation.

  StimDust UC Berkeley

  Untested — nothing else bears on it yet

• StimDust specifically targets deep-tissue electroceuticals by harvesting acoustic energy to trigger therapeutic muscle and nerve responses, unlike original Smart Dust concepts which sought distributed environmental sensing.

  While original Smart Dust concepts sought distributed environmental sensing, StimDust specifically targets deep-tissue electroceuticals by harvesting acoustic energy to trigger therapeutic muscle and nerve responses.

  StimDust

  Untested — nothing else bears on it yet

• Extrapolating these piezoelectric stims to remote airborne behavioral control remains physically impossible because high-frequency ultrasound attenuates rapidly in atmospheric air compared to mammalian tissue.

  Extrapolating these piezoelectric stims to remote airborne behavioral control remains physically impossible because high-frequency ultrasound attenuates rapidly in atmospheric air compared to mammalian tissue.

  Untested — nothing else bears on it yet

• Iota Biosciences and its parent company Astellas Pharma maintain exclusive commercialization pipelines for ultrasonic implants delivering bioelectronic stims.

  Commercial developer Iota Biosciences and parent company Astellas Pharma maintain exclusive commercialization pipelines for ultrasonic implants delivering bioelectronic stims.

  Astellas Pharma Iota Biosciences

  Untested — nothing else bears on it yet

• Security risks emerge from unencrypted acoustic transmission channels, which could allow unauthorized ultrasound transceivers to hijack nerve stims or extract electrophysiological telemetry.

  Security risks emerge from unencrypted acoustic transmission channels, which could allow unauthorized ultrasound transceivers to hijack nerve stims or extract electrophysiological telemetry.

  Untested — nothing else bears on it yet

• Concentrating bioelectronic IP within pharmaceutical conglomerates limits public oversight regarding default cryptographic standards on implantable transceivers.

  Concentrating bioelectronic IP within pharmaceutical conglomerates limits public oversight regarding default cryptographic standards on implantable transceivers.

  Untested — nothing else bears on it yet

• DARPA shifted research funding away from 1990s airborne Smart Dust swarms toward targeted medical stims under the ElectRx bioelectronics program.

  DARPA shifted research funding away from 1990s airborne Smart Dust swarms toward targeted medical stims under the ElectRx bioelectronics program.

  DARPA

  Untested — nothing else bears on it yet

• Historical deployments of distributed micro-electromechanical systems proved that open-air sensor dust failed due to wind dispersion, battery discharge, and signal loss, prompting researchers to repurpose micro-transducers into deep-tissue implants.

  Historical deployments of distributed micro-electromechanical systems proved that open-air sensor dust failed due to wind dispersion, battery discharge, and signal loss, prompting researchers to repurpose micro-transducers into deep-tissue implants.

  Untested — nothing else bears on it yet

• The evolutionary path of micro-sensors demonstrates a move toward surgical therapeutics rather than atmospheric surveillance networks.

  The evolutionary path of micro-sensors demonstrates a move toward surgical therapeutics rather than atmospheric surveillance networks.

  Untested — nothing else bears on it yet

• Patients receiving implantable nerve stims depend on FDA medical device regulations and HIPAA privacy rules to govern bioelectronic data flows.

  Patients receiving implantable nerve stims depend on Food and Drug Administration medical device regulations and HIPAA privacy rules to govern bioelectronic data flows.

  FDA HIPAA

  Untested — nothing else bears on it yet

• Current federal enforcement frameworks under the FTC leave affected individuals without legal remedy against unauthorized external acoustic beam exposure.

  However, current federal enforcement frameworks under the Federal Trade Commission leave affected individuals without legal remedy against unauthorized external acoustic beam exposure.

  FTC

  Untested — nothing else bears on it yet

• Protecting bodily autonomy against unauthenticated acoustic stims requires mandatory hardware-level encryption standards and physical acoustic shielding barriers.

  Protecting bodily autonomy against unauthenticated acoustic stims requires mandatory hardware-level encryption standards and physical acoustic shielding barriers.

  Untested — nothing else bears on it yet

No claims match this filter.

What it cost

Reading this document into the graph cost <$0.01.

12 claims in all. Content fingerprint 307a0b5f64ea… — the document's text itself is not republished here; follow the link above to read it at its source.